Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes

Wang,Wei‑Dong; Xing,Lin; Teng,Jun‑Ru; Li,Shuo; Mi,Na

doi:10.3892/etm.2015.2428

Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes

Authors:
- Wei‑Dong Wang
- Lin Xing
- Jun‑Ru Teng
- Shuo Li
- Na Mi
View Affiliations

Affiliations: Department of Endocrinology, The Third People's Hospital of Jinan, Jinan, Shandong 250132, P.R. China, Department of Clinical Laboratory, The Third People's Hospital of Jinan, Jinan, Shandong 250132, P.R. China
Published online on: April 17, 2015 https://doi.org/10.3892/etm.2015.2428
Pages: 2219-2224

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the effects of basal insulin application on the serum visfatin and adiponectin (APN) levels of patients with type 2 diabetes mellitus (T2DM). A total of 200 patients with T2DM, who were diagnosed in The Third People's Hospital of Jinan (glycosylated hemoglobin ≥7%), were randomly divided into treatment and control groups. The patients used only oral hypoglycemic drugs and had never received insulin therapy. In the treatment group, basal insulin was administered in combination with the original application of oral hypoglycemic drugs, whereas the control group maintained the original use of oral hypoglycemic drugs or took other oral hypoglycemic agents. The body mass index and fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, visfatin, APN and blood lipid levels of the patients were examined prior to the treatment and six months later. The drug and insulin doses in the treatment group were adjusted according to the patients' blood glucose, which allowed the fasting and postprandial blood glucose levels to attain the standards. The fasting and postprandial blood glucose levels in the control group also achieved the standards. It was found that the six‑month application of basal insulin could significantly decrease the glycosylated hemoglobin and significantly increase the serum APN levels; the serum visfatin levels, however, remained unchanged. The immediate application of basal insulin could facilitate the attainment of glycosylated hemoglobin standards in T2DM and could increase the plasma APN levels, preventing diabetic vascular complications.

View Figures

View References

1	Robetson RP, Harmon J, Tran PO, Tanaka Y and Takahashi H: Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathi-one connection. Diabetes. 52:581–587. 2003. View Article : Google Scholar : PubMed/NCBI
2	Cobitz AR and Ambery P: Medical management of hyperglycemia in type 2 type diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Response to Nathan et al. Diabetes Care. 32:e582009. View Article : Google Scholar
3	Swinnen SG, Dain MP, Aronson R, et al: A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 33:1176–1178. 2010. View Article : Google Scholar : PubMed/NCBI
4	Riddle MC, Rosenstock J and Gerich J: Insulin Glargine 4002 Study Investigators: The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 26:3080–3086. 2003. View Article : Google Scholar : PubMed/NCBI
5	Janka HU, Plewe G, Riddle MC, et al: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 28:254–259. 2005. View Article : Google Scholar : PubMed/NCBI
6	Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al: Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia. 49:442–451. 2006. View Article : Google Scholar : PubMed/NCBI
7	Lepore M, Pampanelli S, Fanelli C, et al: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 49:2142–2148. 2000. View Article : Google Scholar : PubMed/NCBI
8	Stentz FB, Umpierrez GE, Cuervo R and Kitabchi AE: Proinflammatory cyto-kines, markers of cardiovascular risks, oxidative stress, and lip id peroxidetion in patients with hyperglycemic crises. Diabetes. 53:2079–2086. 2004. View Article : Google Scholar : PubMed/NCBI
9	Forouhi NG, Sattar N and McKeigue PM: Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 25:1327–1331. 2001. View Article : Google Scholar : PubMed/NCBI
10	Nayak BS, Ramsingh D, Gooding S, et al: Plasma adiponectin levels are related to obesity, inflammation, blood lipids and insulin in type 2 diabetic and non-diabetic Trinidadians. Prim Care Diabetes. 4:187–192. 2010. View Article : Google Scholar : PubMed/NCBI
11	Winkler C and Cseh K: Molecular mechanisms and correlations of insulin resistance, obesity, and type 2 diabetes mellitus. Orv Hetil. 150:7717802009.(In Hungarian). View Article : Google Scholar : PubMed/NCBI
12	Inoue M, Maehata E, Yano M, Taniyama M and Suzuki S: Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism. 54:281–286. 2005. View Article : Google Scholar : PubMed/NCBI
13	Lindsav RS, Funabashi T, Hanson RL, et al: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 360:57–58. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kubota N, Terauchi Y, Yamauchi T, et al: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 277:25863–25866. 2002. View Article : Google Scholar : PubMed/NCBI
15	Stefan N, Stumvoll M, Vozarova B, et al: Plasma adiponectin and endogenous glucose production in humans. Diabetes Care. 26:3315–3319. 2003. View Article : Google Scholar : PubMed/NCBI
16	Hivert MF, Sullivan LM, Shrader P, et al: Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. Diabetologia. 54:1019–1024. 2011. View Article : Google Scholar : PubMed/NCBI
17	Lau CH and Muniandy S: Adiponectin and resistin gene polymorphisms in association with their respective adipokine levels. Ann Hum Genet. 75:370–382. 2011. View Article : Google Scholar : PubMed/NCBI
18	Chu CH, Lam HC, Lee JK, et al: Hyperthyroidism-associated insulin resistance is not mediated by adiponectin levels. J Thyroid Res. 2011:1947212011. View Article : Google Scholar : PubMed/NCBI
19	Wolf AM, Wolf D, Rumpold H, Enrich B and Tilg H: Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 323:630–635. 2004. View Article : Google Scholar : PubMed/NCBI
20	Imai S: Nicotinamide phosphoribosyltansferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des. 15:20–28. 2009. View Article : Google Scholar : PubMed/NCBI
21	Lin Y, Berg AH, Iyengar P, et al: The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem. 280:4617–4626. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yang W, Lu J, Weng J, et al: Prevalence of diabetes among men and women in China. N Engl J Med. 362:1090–1101. 2010. View Article : Google Scholar : PubMed/NCBI
23	Chen MP, Chung FM, Chang DM, et al: Elevated plasma level of vifatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 91:295–299. 2006. View Article : Google Scholar : PubMed/NCBI
24	Jalovaara K, Santaniemi M, Timonen M, et al: Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population. Metabolism. 57:1130–1134. 2008. View Article : Google Scholar : PubMed/NCBI
25	Su SC, Pei D, Hsieh CH, et al: Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes. Acta Diabetol. 48:113–119. 2011. View Article : Google Scholar : PubMed/NCBI
26	Wong WT, Tian XY, Xu A, et al: Adiponectin is required for PPAR൞-mediated improvement of endothelial function in diabetic mice. Cell Metab. 14:104–105. 2011. View Article : Google Scholar : PubMed/NCBI
27	Choudhary S, Sinha S, Zhao Y, et al: NF-kappaB-inducing kinase (NIK) mediates skeletal muscle insulin resistance: blockade by adiponectin. Endocrinology. 152:3622–3627. 2011. View Article : Google Scholar : PubMed/NCBI
28	Skrabal CA, Czaja J, Honz K, et al: Adiponectin - its potential to predict and prevent coronary artery disease. Thorac Cardiovasc Surg. 59:201–206. 2011. View Article : Google Scholar : PubMed/NCBI
29	Kyriazi E, Tsiotra PC, Boutati E, et al: Effects of adiponectin in TNF-α, IL-6, IL-10 cytokine production from coronary artery disease macrophages. Horm Metab Res. 43:537–544. 2011. View Article : Google Scholar : PubMed/NCBI
30	Tesauro M, Rizza S, Iantorno M, et al: Vascular, metabolic, and inflammatory abnormalities in normoglycemic offspring of patients with type 2 diabetes mellitus. Metabolism. 56:413–419. 2007. View Article : Google Scholar : PubMed/NCBI
31	Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 27:813–823. 2004. View Article : Google Scholar : PubMed/NCBI
32	Donath MY and Shoelson SE: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 11:98–107. 2011. View Article : Google Scholar : PubMed/NCBI
33	Cai XJ, Chen L, Li L, et al: Adiponectin inhibits lipopolysaccharide-induced adventitial fibroblast migration and transition to myofibroblasts via AdipoR1-AMPK-iNOS pathway. Mol Endocrinol. 24:218–228. 2010. View Article : Google Scholar : PubMed/NCBI
34	Fagerberg B, Kellis D, Bergstrom G and Behre CJ: Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: a prospective study in 64-year-old women. J Intern Med. 269:636–643. 2011. View Article : Google Scholar : PubMed/NCBI
35	Ran J, Xiong X, Liu W, et al: Increased plasma adiponectin closely associates with vascular endothelial dysfunction in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract. 88:177–183. 2010. View Article : Google Scholar : PubMed/NCBI
36	Curat CA, Wegner V, Sengenes C, et al: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 49:744–747. 2006. View Article : Google Scholar : PubMed/NCBI
37	Dahl TB, Yndestad A, Skjelland M, et al: Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 115:972–980. 2007. View Article : Google Scholar : PubMed/NCBI
38	Adya R, Tan BK, Chen J and Randeva HS: Nuclear factor-kappaB induction by visfatin in human vascular endothelial ceils: its role in MMP-2/9 production and activation. Diabetes Care. 31:758–760. 2008. View Article : Google Scholar : PubMed/NCBI
39	Kim SR, Jung YH, Park HJ, et al: Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells. Biochem Biophys Res Commun. 418:662–668. 2012. View Article : Google Scholar : PubMed/NCBI
40	Kadoglou NP, Sailer N, Moumtzouoglou A, et al: Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 118:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
41	Sethi JK and Vidal-Puig A: Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med. 11:344–347. 2005. View Article : Google Scholar : PubMed/NCBI
42	Samal B, Sun Y, Stearns G, Xie C, Suggs S and McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 14:1431–1437. 1994.PubMed/NCBI
43	Hug C and Lodish HF: Medicine. Visfatin: a new adipokine. Science. 307:366–367. 2005. View Article : Google Scholar : PubMed/NCBI
44	Retnakaran R, Youn BS, Liu Y, et al: Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf). 69:885–893. 2008. View Article : Google Scholar : PubMed/NCBI
45	Holman RR, Paul SK, Bethel MA, Matthews DR and Neil HA: 10-year follow-up of intensive glucose control in 2 type diabetes. N Engl J Med. 359:1577–1589. 2008. View Article : Google Scholar : PubMed/NCBI
46	Forst T, Larbig M, Hobberg C, et al: Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes. Diabetes Obes Metab. 12:437–441. 2010. View Article : Google Scholar : PubMed/NCBI